Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591911 | 0.88 | MAOB (0.52) | HSD17B10MAPK1HPGDALDH1A1KDM4E | |
| SCHEMBL18611964 | 0.88 | MAOB (0.52) | MAPK1ALDH1A1MAOBLMNASLC2A1 | |
| SCHEMBL12848549 | 0.86 | ALDH1A1 (0.53) | HSD17B10MAPK1HPGDALDH1A1KDM4E | |
| SCHEMBL13359316 | 0.85 | KDM4E (0.54) | HSD17B10MAPK1HPGDALDH1A1KDM4E | |
| SCHEMBL2236147 | 0.85 | ALDH1A1 (0.58) | HSD17B10MAPK1HPGDALDH1A1KDM4E | |
| SCHEMBL9119332 | 0.82 | MAOB (0.47) | HSD17B10MAPK1ALDH1A1KDM4EMAOB | |
| SCHEMBL12795499 | 0.82 | KDM4E (0.51) | HSD17B10MAPK1ALDH1A1KDM4EMAOB | |
| SCHEMBL648621 | 0.81 | MAOB (0.70) | HPGDALDH1A1KDM4EMAOBMAPT | |
| SCHEMBL8118515 | 0.81 | MAOB (0.55) | HSD17B10HPGDALDH1A1KDM4EMAOB | |
| SCHEMBL10963543 | 0.80 | CA12 (0.54) | HSD17B10MAPK1HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | claimed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | claimed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| EP-1068304-A4 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORP (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1068304-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | HSD17B10 1674/4885MAPK1 4288/4885HPGD 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.